Adial Pharmaceuticals Overview
- Year Founded
-
2010
- Status
-
Public
- Employees
-
6
- Stock Symbol
-
AZR
- Investments
-
2
- Share Price
-
$3.80
- (As of Wednesday Closing)
Adial Pharmaceuticals General Information
Description
Azora Therapeutics Inc is a biopharmaceutical company focused on developing treatments for serious inflammatory diseases. Azora owns the royalty-free rights to its technology, which is based on the development of potential best-in-class oral agonists of the aryl hydrocarbon receptor. Azora's lead program is AT177, a proprietary colon-targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure in development for ulcerative colitis.
Contact Information
Website
www.adial.comCorporate Office
- 4870 Sadler Road
- Suite 300
- Glen Allen, VA 23060
- United States
Corporate Office
- 4870 Sadler Road
- Suite 300
- Glen Allen, VA 23060
- United States
Adial Pharmaceuticals Timeline
Adial Pharmaceuticals Stock Performance
As of 18-Nov-2026, Adial Pharmaceuticals’s stock price is $3.80. Its current market cap is $54.3M with 14.3M shares.
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.80 | $3.67 | $1.31 - $8.22 | $54.3M | 14.3M | 49.9K | -$17.99 |
Adial Pharmaceuticals Financials Summary
As of 30-Sep-2026, Adial Pharmaceuticals has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 20,351 | 1,257 | 1,335 | 1,950 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (120,888) | (8,126) | (13,376) | (7,071) |
| Net Income | (120,570) | (7,977) | (13,197) | (5,123) |
| Total Assets | 22,528 | 6,673 | 5,044 | 4,737 |
| Total Debt | 0 | 0 | 0 | 0 |
Adial Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Adial Pharmaceuticals Comparisons
Industry
Financing
Details
Adial Pharmaceuticals Competitors (9)
One of Adial Pharmaceuticals’s 9 competitors is Indivior, a Corporate Backed or Acquired company based in North Chesterfield, VA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Indivior | Corporate Backed or Acquired | North Chesterfield, VA | ||||
| AVEO Oncology | Formerly VC-backed | Boston, MA | ||||
| Blueprint Medicines | Formerly VC-backed | Cambridge, MA | ||||
| Alkermes | Formerly VC-backed | Dublin, Ireland | ||||
| Aptevo Therapeutics | Corporation | Seattle, WA |
Adial Pharmaceuticals Patents
Adial Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260345557-A1 | Ondansetron treatment of alcohol use disorder | Pending | 05-Jul-2024 | ||
| WO-2026011119-A1 | Ondansetron treatment of alcohol use disorder | Pending | 05-Jul-2024 | ||
| EP-3372532-A1 | Carriage for an automatic dispenser of prepared food products, notably pizza | Inactive | 07-Mar-2017 | ||
| US-20180257862-A1 | Carriage for an automatic dispenser of prepared food products, notably pizza | Inactive | 07-Mar-2017 | ||
| FR-3063718-A1 | Trolley for automatic dispenser of prepared food products, in particular pizza | Active | 07-Mar-2017 | B65G1/137 |
Adial Pharmaceuticals Signals
Adial Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Adial Pharmaceuticals Acquisitions (2)
Adial Pharmaceuticals’s most recent deal was a Merger/Acquisition with Azora Therapeutics. The deal was made on 11-Jun-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Azora Therapeutics | 11-Jun-2026 | Merger/Acquisition | Drug Discovery | ||
| Purnovate | 26-Jan-2021 | Merger/Acquisition | Drug Discovery |
Adial Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
41.09 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Adial Pharmaceuticals Exits (1)
Adial Pharmaceuticals’s most recent exit was on 26-Jan-2021 from Purnovate. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Purnovate | 26-Jan-2021 | Completed |
|
Adial Pharmaceuticals FAQs
-
When was Adial Pharmaceuticals founded?
Adial Pharmaceuticals was founded in 2010.
-
Where is Adial Pharmaceuticals headquartered?
Adial Pharmaceuticals is headquartered in Glen Allen, VA.
-
What is the size of Adial Pharmaceuticals?
Adial Pharmaceuticals has 6 total employees.
-
What industry is Adial Pharmaceuticals in?
Adial Pharmaceuticals’s primary industry is Pharmaceuticals.
-
Is Adial Pharmaceuticals a private or public company?
Adial Pharmaceuticals is a Public company.
-
What is Adial Pharmaceuticals’s stock symbol?
The ticker symbol for Adial Pharmaceuticals is AZR.
-
What is the current stock price of Adial Pharmaceuticals?
As of 18-Nov-2026 the stock price of Adial Pharmaceuticals is $3.80.
-
What is the current market cap of Adial Pharmaceuticals?
The current market capitalization of Adial Pharmaceuticals is $54.3M.
-
Who are Adial Pharmaceuticals’s competitors?
Indivior, AVEO Oncology, Blueprint Medicines, Alkermes, and Aptevo Therapeutics are some of the 9 competitors of Adial Pharmaceuticals.
-
What is Adial Pharmaceuticals’s annual earnings per share (EPS)?
Adial Pharmaceuticals’s EPS for 12 months was -$17.99.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process